Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Oncotelic Therapeutics, Inc. (OTLC : OTC)
 
 • Company Description   
Mateon is a biopharmaceutical company focused on the modulation of transforming growth factor-beta (TGF-beta) for the treatment of cancer and infectious diseases, including COVID-19. The company's lead development compound, OT-101 (trabedersen), is a single stranded antisense oligonucleotide targeting the TGF-beta2 mRNA. Mateon is conducting a Phase 2/3 clinical trial of OT-101 in patients suffering from COVID-19. In addition, the company has initiated a global Phase 4 clinical trial of ArtiShield(TM) in India, Africa, and Latin America for the treatment of COVID-19, with results expected in the 4Q20. ArtiShieldTM received marketing approval from India.

Number of Employees: 16

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.21 Daily Weekly Monthly
20 Day Moving Average: 110,924 shares
Shares Outstanding: 377.61 (millions)
Market Capitalization: $79.30 (millions)
Beta: 0.75
52 Week High: $0.33
52 Week Low: $0.08
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.67% 2.27%
12 Week -3.45% 4.76%
Year To Date 25.15% 48.82%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
29397 AGOURA ROAD SUITE 107
-
AGUORA HILLS,CA 91301
USA
ph: 650-635-7000
fax: 650-635-7001
info@oncotelic.com http://www.oncotelic.com
 
 • General Corporate Information   
Officers
Vuong Trieu - Chairman and Chief Executive Officer
Amit Shah - Chief Financial Officer
Saran Saund - Chief Business Officer
Steven W. King - Director
Anthony E. Maida - Director

Peer Information
Oncotelic Therapeutics, Inc. (CORR.)
Oncotelic Therapeutics, Inc. (RSPI)
Oncotelic Therapeutics, Inc. (CGXP)
Oncotelic Therapeutics, Inc. (BGEN)
Oncotelic Therapeutics, Inc. (GTBP)
Oncotelic Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 628341109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 05/23/22
Share - Related Items
Shares Outstanding: 377.61
Most Recent Split Date: 12.00 (0.08:1)
Beta: 0.75
Market Capitalization: $79.30 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.00 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.02 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/23/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 9.63
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -101.27
09/30/21 - -111.13
ROA
03/31/22 - -
12/31/21 - -39.75
09/30/21 - -48.68
Current Ratio
03/31/22 - -
12/31/21 - 0.04
09/30/21 - 0.01
Quick Ratio
03/31/22 - -
12/31/21 - 0.04
09/30/21 - 0.01
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 0.02
09/30/21 - 0.02
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©